These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22511706)

  • 1. Paraoxonase 1 Q192R variant and clopidogrel efficacy: fact or fiction?
    Lewis JP; Shuldiner AR
    Circ Cardiovasc Genet; 2012 Apr; 5(2):153-5. PubMed ID: 22511706
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events.
    Paré G; Ross S; Mehta SR; Yusuf S; Anand SS; Connolly SJ; Fox KA; Eikelboom JW
    Circ Cardiovasc Genet; 2012 Apr; 5(2):250-6. PubMed ID: 22368149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.
    Li X; Zhang L; Chen X; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Xu Q; Zhang Y; Li Y; Lu C; Yin T
    Thromb Res; 2013 Oct; 132(4):444-9. PubMed ID: 23993903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis.
    Reny JL; Combescure C; Daali Y; Fontana P;
    J Thromb Haemost; 2012 Jul; 10(7):1242-51. PubMed ID: 22520065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.
    Trenk D; Hochholzer W; Fromm MF; Zolk O; Valina CM; Stratz C; Neumann FJ
    Circ Cardiovasc Genet; 2011 Aug; 4(4):429-36. PubMed ID: 21685174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response.
    Lewis JP; Fisch AS; Ryan K; O'Connell JR; Gibson Q; Mitchell BD; Shen H; Tanner K; Horenstein RB; Pakzy R; Tantry US; Bliden KP; Gurbel PA; Shuldiner AR
    Clin Pharmacol Ther; 2011 Oct; 90(4):568-74. PubMed ID: 21881565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paraoxonase-1 is a major determinant of clopidogrel efficacy.
    Bouman HJ; Schömig E; van Werkum JW; Velder J; Hackeng CM; Hirschhäuser C; Waldmann C; Schmalz HG; ten Berg JM; Taubert D
    Nat Med; 2011 Jan; 17(1):110-6. PubMed ID: 21170047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
    Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M
    Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants.
    Martínez-Quintana E; Medina-Gil JM; Rodríguez-González F; Garay-Sánchez P; Limiñana JM; Saavedra P; Tugores A
    J Clin Pharmacol; 2014 Aug; 54(8):843-9. PubMed ID: 24504666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes.
    Mega JL; Close SL; Wiviott SD; Man M; Duvvuru S; Walker JR; Sundseth SS; Collet JP; Delaney JT; Hulot JS; Murphy SA; Paré G; Price MJ; Sibbing D; Simon T; Trenk D; Antman EM; Sabatine MS
    J Thromb Thrombolysis; 2016 Apr; 41(3):374-83. PubMed ID: 26573179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors that contribute to clopidogrel resistance in cardiovascular disease patients: environmental and genetic approach.
    Al-Azzam SI; Alzoubi KH; Khabour OF; Nusair MB; Al-Hadidi H; Awidi A; Saleh A
    Int J Clin Pharmacol Ther; 2013 Mar; 51(3):179-86. PubMed ID: 23357840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction.
    Simon T; Steg PG; Becquemont L; Verstuyft C; Kotti S; Schiele F; Ferrari E; Drouet E; Grollier G; Danchin N
    Clin Pharmacol Ther; 2011 Oct; 90(4):561-7. PubMed ID: 21918510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Indications of treatment with clopidogrel in the guidelines of the Spanish Society of Cardiology for unstable angina/non-ST-segment elevation acute myocardial infarction].
    Valentín Segura V
    Rev Esp Cardiol; 2002 Nov; 55(11):1217-8; author reply 1218. PubMed ID: 12423582
    [No Abstract]   [Full Text] [Related]  

  • 15. [Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions].
    Niessner A; Niessner H; Huber K
    Herz; 2001 Apr; 26 Suppl 1():36-41. PubMed ID: 11349625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with clopidogrel and aspirin: can the CURE results be extrapolated to cerebrovascula patients?
    Albers GW; Amarenco P
    Stroke; 2001 Dec; 32(12):2948-9. PubMed ID: 11740003
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective.
    Berger PB; Steinhubl S
    Circulation; 2002 Oct; 106(17):2284-7. PubMed ID: 12390961
    [No Abstract]   [Full Text] [Related]  

  • 18. Paraoxonase-1 and clopidogrel efficacy.
    Cuisset T; Morange PE; Quilici J; Bonnet JL; Gachet C; Alessi MC
    Nat Med; 2011 Sep; 17(9):1039; author reply 1042-4. PubMed ID: 21900913
    [No Abstract]   [Full Text] [Related]  

  • 19. Paraoxonase-1 and clopidogrel efficacy.
    Dansette PM; Rosi J; Bertho G; Mansuy D
    Nat Med; 2011 Sep; 17(9):1040-1; author reply 1042-4. PubMed ID: 21900914
    [No Abstract]   [Full Text] [Related]  

  • 20. Paraoxonase-1 and clopidogrel efficacy.
    Camps J; Joven J; Mackness B; Mackness M; Tawfik D; Draganov D; Costa LG; Paragh G; Seres I; Horke S; James R; Hernández A; Reddy S; Shih D; Navab M; Rochu D; Aviram M
    Nat Med; 2011 Sep; 17(9):1041-2; author reply 1042-4. PubMed ID: 21900915
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.